Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
131 Leser
Artikel bewerten:
(0)

TeleVox Applauded by Frost & Sullivan for Improving Patient Experience through Effective Engagement and Customer Value

TeleVox's highly flexible platform provides PRM capabilities covering the full extent of healthcare stakeholders, enhancing the patient population experience, decreasing missed appointments, and facilitating better care outcomes.

SAN ANTONIO, Oct. 28, 2024 /PRNewswire/ -- Frost & Sullivan recently assessed the patient relationship management (PRM) industry and, based on its findings, recognizes TeleVox with the 2024 North American Customer Value Leadership Award. The company provides meaningful, omnichannel interactions that span the patient journey-scheduling, intake, appointment, and post-visit engagement. TeleVox's platform empowers personalization and scalability to a client's entire population base. The platform integrates with physician-patient portals and EHRs in a meaningful manner, pulling in patient-specific information customized to client specifications and allowing the information to be tailored to patient-specific context. As such, it augments the patient experience by allowing them to perform actions in a portal in an easy, self-service manner.

TeleVox

TeleVox has a comprehensive portfolio of best-in-breed solutions that cover the holistic patient journey, including preventative care, discovery care, specialty diagnosis and treatment, appointment booking and preparation, and chronic disease management. This comprehensive portfolio is a key differentiator for TeleVox, as it bridges the gap across various touchpoints in the patient journey, irrespective of where the patient is in the process. It ensures easier provider access to functionalities or viewpoints, enabling providers to track more patients at scale without additional manual work while improving clinical outcomes and operational benefits. The company also offers a continuous delivery framework, giving customers immediate value through updates with more features, functionalities, enhancements, and upgrades. TeleVox's new AI-enabled, Virtual Agent and chat solutions help health systems deliver an enhanced self-service experience that aligns with consumer communication expectations and workflows outside the healthcare industry.

Delfina Huergo, healthcare industry analyst for Frost & Sullivan, observed, "TeleVox sets out to overcome the shortcomings of the PRM industry. The company bridges the gap by providing an experience that covers the patient journey from initial appointment to post-discharge, including chronic disease management. TeleVox offers a unified strategy for customers and patients, bringing consistent, persistent, and actionable conversation through artificial intelligence capabilities to facilitate thoughtful engagement longitudinally."

TeleVox offers a true omnichannel scenario that allows patients to leverage voice, web, or short message service (SMS) text communication channels based on their preferences. Patients have access to the same experience, personalization, and automation regardless of their chosen channel. TeleVox's new Practice Edition solution gives practice groups of less than 50 providers a streamlined method to manage their day. It provides administrators tools specific to a practice level in a single interface, including scheduling appointments, managing wait lists, rescheduling, website management, marketing, ad hoc alerts, and adding emergency appointments. This reduces the barrier for smaller providers to offer a better patient experience, thereby improving outcomes such as filling schedules, increasing revenue capture, and enhancing patient satisfaction overall. TeleVox's customization and expertise ensure that patients have valuable and positive experiences when interacting with the platform regardless of their chosen channel, thereby enhancing patient loyalty and continuous use. With its multiple pricing models, the company enacts high value and ROI for customers regardless of size or application.

"TeleVox provides unmatched customer service, working with customers to customize engagement projects aligned to a client's specific goals and endpoints, maximizing overall value, and achieving high return on investment. Its low/no code configuration enables fast and flexible workflow integration, empowering it to align workflows and integrate updated solutions and features efficiently," added Huergo. TeleVox earns Frost & Sullivan's 2024 North American Customer Value Leadership Award for its strong overall performance in the patient relationship management industry.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognizes the company's unique focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention and customer base expansion.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion.

Contact:

Camila Tinajero
P: +54911 6713 2748
E: Camila.Tinajero@frost.com

Photo - https://mma.prnewswire.com/media/2530068/TeleVox_Award.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/televox-applauded-by-frost--sullivan-for-improving-patient-experience-through-effective-engagement-and-customer-value-302275512.html

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.